Article Details

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor ...

Retrieved on: 2021-08-18 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor .... View article details on hiswai:

Excerpt

(NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of ...

Article found on: finance.yahoo.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up